



Biocure Technology

February 8, 2018

FOR IMMEDIATE RELEASE

BioCure Announces Appointment of an Advisory Committee and AGM Results

Vancouver, British Columbia – February 8, 2018 – Biocure Technology Inc. (formerly Gravis Energy Corp.) (CSE: CURE) (the “**Company**” or “**Biocure**”) is pleased to announce the formation of a new advisory committee who will support management in advancing the Company. The company welcomes the members, Jae Soo Shin, Heon Ju Lee and Hyun Soo Lee to the Biocure team.

Their combined expertise and experience will be a great asset in advancing the Company and helping bridge the business in Korea to North America.

“Bringing such an experienced advisory committee to BioCure allows the Company to benefit from their depth of medical knowledge and industry-focused strategic thinking,” said Dr. Sang Mok Lee, President and CEO, *“I am very excited to have these three well known and highly experienced individuals join the BioCure team, for them to contribute their invaluable expertise and experience to the Company for the benefit of our shareholders and to assist the Company with moving forward to reaching there milestones.”*

In addition, the Company is pleased to announce the re-election of Sang Mok Lee, Sang Goo Kim, Julie Hajduk and Anna Dalairé to the Board of Directors at the Annual General Meeting on February 7th, 2018. The shareholders also passed all other resolutions including ordinary resolutions to: (i) appoint the auditor of the Company for the year; and (ii) approve the Company’s stock option plan.

The Company also announces the appointment of Sang Goo Kim as the Company’s Chief Financial Officer and Corporate Secretary. Mr. Kim replaces Nizar Bharmal as Chief Financial Officer. The Company wishes to thank Mr. Bharmal for his services to the Company and wish him the best for his future endeavours.

New Advisory Board Members

JAE SOO SHIN, PH. D., MANAGING DIRECTOR OF IL-YANG PHARM. CO. LTD. KOREA

Mr. Shin is a pharmacist and also holds a Ph.D. in Pharmacology from Seoul National University in Korea and is currently an adjunct professor at KonKuk University Medical School. He had worked as a chief of pharmacology & toxicology Lab. in the preclinical development of new drugs in Chong Kun Dang Pharmaceutical Corp. for 21 years. Since 2008, he has been working as a managing director for IL-YANG Pharm. Co. Ltd., being responsible for preclinical and clinical development of new drugs and several vaccines for human and avian influenza. Since 2013, he has also been a member of policy advisory committee of KSAP (The Korean Society of Applied Pharmacology).

HEON JU LEE, PH.D.

Dr. Lee holds Bachelor's and Master's degrees in Microbiology from Seoul National University in Korea and a Ph.D. in Environmental Toxicology from Hankuk University of Foreign Studies. For 29 years, he worked on the development of biopharmaceuticals in CJ Inc. and Samsung Group; and conducted nonclinical animal testing and licensing work for drug development in Korea Institute of Toxicology. Currently, he is the vice-president of BiocurePharm, leading the pre-clinical and clinical development of biopharmaceuticals such as interferon beta and CAR-T immune cell therapy products. Since 2011, he has been a member of the Institutional Review Board (IRB) and a Certified Toxicology Professional in Korea.

HYUN SOO LEE, PH.D.

Dr. Lee holds a Ph.D. in molecular biotechnology from Korea Advanced Institute of Science and Technology in Korea. He has worked as a senior researcher in charge of the development of a variety of biopharmaceuticals in CJ Inc. (1987 ~ 2005), and as Director of research institute of JW Creagene Inc. (2005 ~ 2012) developing immune-cell therapies. He is currently Director of research institute of Pharos Vaccine Inc. and a non-executive director of Arogen Inc.

Lastly, Sang Mok Lee, President & CEO and Collin Kim, CFO & Director of Biocure Technology will be attending at the Capital Event Conference in Whistler British Columbia from Friday Feb 9 - Sunday Feb 11th, 2018

About Biocure

Biocure is a South Korean based Bio Pharmaceutical company specializing in the development and potential commercialization of biosimilar pharmaceutical products. Biocure is in the process of pre-clinical trials of five major biosimilar products in South Korea, including Interferon Beta 1b, PEG-Filgrastim and Ranibizumab as well as CAR-T Cell Therapy. Interferon Beta 1b is used for treating relapsing forms of multiple sclerosis ("MS") Filgrastim is used to treat neutropenia, a lack of certain white blood cells caused by bone marrow transplants, chemotherapy, and other conditions. Ranibizumab is used for treating macular degeneration. It is also used to treat a type of eye problem known as macular edema, as well as certain eye problems caused by diabetes. Biocure is also developing a foot and mouth disease vaccine, a hair growth production product and a breast cancer detection kit.

ON BEHALF OF THE BOARD OF DIRECTORS

/s/ "Sang Mok Lee"
CEO and Director

For further information, please contact:

Biocure Technology Inc. Telephone: 604-609-7149

Certain statements in this news release, which are not historical in nature, constitute "forward looking statements" within the meaning of that phrase under applicable Canadian securities law. These statements include, but are not limited to, statements or information concerning the Company's proposed activities under the Agreement, the Company's ability to achieve sales, commercial or otherwise, from its products, and the expectations of the Company regarding funding payments due pursuant to the Agreement. These statements reflect management's current assumptions and expectations and by their nature are subject to certain underlying assumptions, known and unknown risks and uncertainties and other factors which may cause actual results, performance or events to be materially different from those expressed or implied by such forward looking statements. Except as required pursuant to applicable securities laws, the Company will not update these forward-looking statements to reflect events or circumstances after the date hereof. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities

regulatory authorities by the Company. Readers are cautioned not to place undue reliance on forward looking statements. Neither the Canadian Securities Exchange (the "CSE") nor the Investment Industry Regulatory Organization of Canada) accepts responsibility for the adequacy or accuracy of this release.